Morgan Stanley Maintains Prime Medicine(PRME.US) With Hold Rating, Cuts Target Price to $5
BMO Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $19
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $10
Prime Medicine Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Prime Medicine's Strategic Alliances and Growth Potential Affirm Buy Rating
Prime Medicine Analyst Ratings
BMO Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $19
A Quick Look at Today's Ratings for Prime Medicine(PRME.US), With a Forecast Between $10 to $19
Buy Rating Reaffirmed for Prime Medicine on Strong Cash Position and Promising Technology Platforms
Prime Medicine, Inc. (PRME) Gets a Hold From Stifel Nicolaus
JonesTrading Initiates Prime Medicine(PRME.US) With Buy Rating, Announces Target Price $14
Analysts Offer Insights on Healthcare Companies: Guardant Health (GH) and Prime Medicine, Inc. (PRME)
Prime Medicine Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $10 Price Target
Buy Rating for Prime Medicine, Inc. on Strong Pipeline and Financial Health
Buy Rating Affirmed for Prime Medicine, Inc. on Strong Clinical Trials and Financial Footing
TD Cowen Sticks to Its Buy Rating for Prime Medicine, Inc. (PRME)
Prime Medicine (PRME.US) was first covered by HC Wainwright & Co. with a buy rating, with a target price of $10.00.
Prime Medicine Analyst Ratings
HC Wainwright & Co. Initiates Coverage On Prime Medicine With Buy Rating, Announces Price Target of $10